Onkologie. 2012:6(5):284-286
Gefitinib in treatment of non-small-cell-lung cancer
- 1 Klinika nemocí plicních a tuberkulózy, FN Brno, Bohunice a LF MU v Brně
- 2 Patologicko-anatomický ústav, FN Brno, Bohunice a LF MU v Brně
- 3 Centrum molekulární biologie a genové terapie při Interní hematoonkologické klinice, FN Brno, Bohunice a LF MU v Brně
Lung carcinoma is the most common cause of death among cancer patients. Non-small-cell-lung cancer is the most frequent histological type of lung carcinoma. Gefitinib is intended for biological treatment of locally advanced or metastatic non-small-cell-lung cancer in patients with activation mutation of epidermal factor growth receptor, in first line of treatment, without previous chemothrapy. Case study discusses two patients treated with gefitinib, with similar initial parameters, but diferent outcomes of the treatment.
Keywords: gefitinib, biological treatment, non-small-cell-lung-cancer, epidermal factor growth receptor
Published: November 1, 2012 Show citation
References
- Tomíšková M, Skřičková J, Hausnerová J, Moulis M, Robešová B, Bajerová M, Dvořáková D. Klinické zkušenosti s gefitinibem v léčbě nemocných s nemalobuněčným karcinomem plic. Farmakoterapie 2012: 2.
- Skřičková J, Pešek M, Kolek V, a kol. Výsledky klinického hodnocení účinnosti a toxicity gefitinibu v rámci programu časného přístupu u nemalobuněčného karcinomu plic v České republice. Stud. Pneumol. Phtiseol. 2009; 69: 62-68.
- Kolektiv autorů Astra Zeneca. Iressa v léčbě nemalobuněčného karcinomu plic (NSCLC), nádory bronchu, plíce a pleury. Nové léky v onkologické praxi 2011: 27-37.
- http://ec.europa.eu/research/health/pdf/event06/12052011/anne-debock_en.pdf.
- Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refraktory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366: 1527-1537.
Go to original source... 
Go to PubMed... - Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818. Go to original source... Go to PubMed...
- Yang CH, Fukuoka M, Mok TS, et al. Final overall survival results from a phase III, randomised, open label, first-line study of gefitinib v. carboplatin/paclitaxel in clinically selected patients with advanced non-small cell lung cancer in Asia (IPASS) Ann Oncol 2010; 21(Suppl. 8): viii122-161. Go to original source... Go to PubMed...
- Herbst RS, LoRusso PM, Purdom M, Ward D. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003; 4(6): 366-369. Go to original source... Go to PubMed...
- Cappuzzo F, Bartolini S, Ceresoli GL, Tamberi S, Spreafico A, Lombardo L, Gregorc V, Toschi L, Calandri C, Villa E, Crin? L. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). British Journal of Cancer 2004; 90: 82-86. doi: 10.1038/sj.bjc.6601470. Go to original source... Go to PubMed...